Get started
HOOKIPA Pharma Inc.HH

HOOKIPA Pharma Inc.

1.23USDR
+0.01+0.82%
At close at Mar 20, 22:03 GMT
USD
No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Forecast Seasonals Options

HOOK fundamentals

Key facts

Market capitalization‪14.83 M‬USD
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−3.55USD
Founded2011
Employees (FY)87
CEOMalte Peters
Websitehookipapharma.com
About

HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The firm also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.

Ownership
‪‪9.66 M‬‬
Free Float shares
‪‪6.88 M‬‬ (71.27%)
Closely held shares
‪‪2.78 M‬‬ (28.73%)
Free Float shares
‪‪6.88 M‬‬ (71.27%)
Closely held shares
‪‪2.78 M‬‬ (28.73%)
Capital structure
Market cap
‪‪14.83 M‬‬
Debt
‪‪875.00 K‬‬
Cash & equivalents
‪‪39.78 M‬‬
Enterprise value
‪‪−24.07 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪14.83 M‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
0.33x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
0.33x
Valuation ratios
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪1.00‬
‪2.00‬
‪3.00‬
‪4.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−2,100.0%‬
‪−1,400.0%‬
‪−700.0%‬
‪0.0%‬
‪700.0%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−40.00 M‬‬
‪‪−20.00 M‬‬
‪0.00‬
‪‪20.00 M‬‬
‪‪40.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−27.00 M‬‬
‪‪−18.00 M‬‬
‪‪−9.00 M‬‬
‪0.00‬
‪‪9.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−27.00 M‬‬
‪‪−18.00 M‬‬
‪‪−9.00 M‬‬
‪0.00‬
‪‪9.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Pharmaceutical Products
By country
Period: 2024
United States

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪10.00 M‬‬
‪‪20.00 M‬‬
‪‪30.00 M‬‬
‪‪40.00 M‬‬
Actual
Estimate
Earnings
Next:May 8, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪−2.00‬
‪−1.00‬
‪0.00‬
‪1.00‬
‪2.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

HOOK does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−40.00 M‬‬
‪0.00‬
‪‪40.00 M‬‬
‪‪80.00 M‬‬
‪‪120.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪21.00 M‬‬
‪‪42.00 M‬‬
‪‪63.00 M‬‬
‪‪84.00 M‬‬
Assets
Liabilities